Dr. Fleming details his early-phase clinical trial work that has had the largest impact on patients with GU malignancies. Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605. Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies. Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC. Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations. Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes. Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer. Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care. A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk. Dr. A. Ari Hakimi discusses how cytoreductive nephrectomy has evolved and is being used in today’s mRCC treatment paradigm. Dr. Sprenkle shares his inspiration to practice urologic oncology and his role in popularizing the Artemis Device. Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel. Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer. Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer. Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC. Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program. David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more. Rishabh Simhal, MD, discusses baseline fatigue and OS in patients with prostate cancer, as well as the FACIT-F questionnaire. Yair Lotan, MD, details the real-world use, effectiveness, and standard-of-care potential of UGN-101 for patients with UTUC. Alex Pozdnyakov, MD, explains the current utility and potential application of PSMA PET imaging in prostate cancer.